Benchmark Holdings has announced that non-executive board member Hugo Wahnish is to resign.
Wahnish has held a board position at the aquaculture genetics, health and advanced nutrition company since November 2017. He will be leaving on 9 February 2021.
The company’s announcement credits him with playing “a significant role” in Benchmark’s transformative period as it divested non-core assets to focus on aquaculture.
Wahnish has nearly 40 years of experience in the animal health and pharmaceuticals industry, firstly with GlaxoSmithKline, and prior to 2012, with Merck where he held the post of chief commercial officer, animal health.
Peter George, chair of Benchmark Genetics, commented: “On behalf of the Board I would like to thank Hugo for his contribution to Benchmark, in particular his support during our restructuring to focus on our core aquaculture areas. We wish him every success in his future endeavours.”